Welcome to our dedicated page for Puma Biotechnology SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
Puma Biotechnology, Inc. reported the results of its annual shareholder meeting. Stockholders elected eight directors, with each nominee receiving more votes "For" than "Withheld." Alan H. Auerbach received 37,130,678 votes "For" and 785,624 "Withheld," while other nominees showed similar support levels.
Shareholders also voted on three additional proposals. One proposal drew 42,612,940 votes "For" and 1,328,476 "Against". Another received 29,326,673 votes "For" and 7,878,580 "Against." A further proposal received 18,234,150 votes "For" and 19,596,238 "Against," indicating it did not obtain majority support.
Puma Biotechnology director Troy Edward Wilson reported both a stock grant and a sale of shares of common stock. He received 27,000 Restricted Stock Units (RSUs) that vest in full on the earlier of one year from grant or the next annual shareholder meeting, subject to his continued service with the company.
Wilson also completed an open-market sale of 10,800 shares at a weighted average price of $7.1989 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03-12-2025. Following these transactions, he holds 59,750 shares directly, plus 550 shares indirectly through accounts for two children.
Puma Biotechnology director Brian M. Stuglik reported both an equity grant and a share sale. On June 11, 2026, he acquired 27,000 shares of common stock at $0.00 per share as a grant of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continued service. On June 12, 2026, he executed an open-market sale of 8,100 common shares at a weighted average price of $7.1989 per share, in multiple trades between $6.98 and $7.32, under a Rule 10b5-1(c) trading plan adopted on March 12, 2025. Following these transactions, he directly holds 113,858 common shares.
PUMA Biotechnology director Adrian Senderowicz reported both an equity grant and a stock sale. On June 11, 2026, he received 27,000 shares of Common Stock as Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continued service.
On June 12, 2026, he sold 27,000 shares of Common Stock in an open-market transaction at a weighted average price of $7.1967 per share, with individual sale prices ranging from $6.98 to $7.32. The sale was effected pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025, and he held 27,000 shares directly after the transactions.
MILLER MICHAEL PATRICK reported acquisition or exercise transactions in this Form 4 filing.
Puma Biotechnology director Michael Patrick Miller received an equity award in the form of restricted stock units. He was granted 27,000 shares of common stock at no cash cost to him, increasing his directly held stake to 81,000 shares after this grant.
The restricted stock units vest in full on the earlier of one year from the grant date or the next annual shareholder meeting, as long as he continues serving the company. This is a compensation-related grant rather than an open-market purchase or sale.
PUMA Biotechnology director Jay M. Moyes reported both an equity grant and a share sale. On June 11, 2026, he received 27,000 shares as a grant described as Restricted Stock Units that vest in full on the earlier of the one-year anniversary of grant or the next annual shareholder meeting, subject to continued service.
On June 12, 2026, he sold 22,000 shares of common stock in an open-market transaction pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025, at a weighted-average price of $7.218 per share across trades ranging from $6.98 to $7.32. Following these transactions, he directly holds 58,322 shares of common stock.
PUMA Biotechnology director Allison Dorval reported both an equity grant and a share sale. On June 11, 2026, she received 27,000 Restricted Stock Units that vest in full on the earlier of the one-year anniversary of grant or the next annual shareholder meeting, subject to continued service. On June 12, 2026, she made an open-market sale of 11,610 common shares at a weighted average price of $7.1989 per share under a Rule 10b5-1(c) trading plan adopted on 03-12-2025. After these transactions, Dorval directly holds 90,780 common shares.
Cesano Alessandra reported acquisition or exercise transactions in this Form 4 filing.
PUMA Biotechnology director Alessandra Cesano reported an equity award of 27,000 shares of Common Stock on June 11, 2026. The award is in the form of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to her continued service with the company.
Following this grant, Cesano directly holds 68,850 shares. This is a compensation-related grant, not an open-market purchase.